Synthesis, in Silico and in Vitro Study on Phase I Metabolism of the Potent 5-Ht7/5-Ht1a/D2 Receptor Ligand: 4-Fluoron -(1-{2-[2-(Methylsulfanyl)- Phenoxy]Ethyl}Pyrrolidin-3-Yl) Benzene Sulfonamide


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

In the present study we analyze the synthesis as well as biotransformation pathways and metabolic stability of 4-fluoro- N -(1-{2-[2-(methylsulfanyl)phenoxy]ethyl}pyrrolidin-3-yl) benzene sulfonamide – thioether compound 5, with the affinity for several subtypes of the serotonin and dopamine receptor. Studies were conducted in vitro on liver microsomes from three species – mouse, rat, and human. The biotransformation was analyzed using liquid chromatography coupled with mass spectrometry. Two major metabolites (M1 and M2) – products of S-oxidation of the parent molecule – were generated both by in silico and in vitro methods. Use of three species allowed us to determine the interspecies differences in metabolic stability of tested compound. Two parameters, t0.5 and Clint , were calculated. Compound 5 was the most stable in human liver microsomes. Results are useful for understanding the interspecies differences in metabolism of the serotonin and dopamine receptor ligand associated with sulfur atom.

About the authors

Paulina Kubowicz-Kwaoeny

Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff2

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street 30-688, Krakow

Kamil Piska

Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff2

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street 30-688, Krakow

Katarzyna Klaoe

Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff2

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street 30-688, Krakow

Pawe Zmudzki

Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff4

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street, 30-688, Krakow

Vittorio Canale

Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff4

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street, 30-688, Krakow

Pawel Zajdel

Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff4

Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street, 30-688, Krakow

Elźbieta Pêkala

Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College; Aff2

Author for correspondence.
Email: elzbieta.pekala@uj.edu.pl
Poland, Cracow; 9 Medyczna Street 30-688, Krakow


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies